Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals Investor Presentation: Key Takeaways

H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.

Accretion Pharmaceuticals Results Update

Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.

Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY

Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.

Key figure

Net profit ₹8.2 Cr · +70.8% YoY

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).

Accretion Pharmaceuticals Other Announcement

Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.

Accretion Pharmaceuticals Annual General Meeting

Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.